Is Perseris a long-acting injectable?

What type of medication is Perseris?

Perseris is a long-acting injectable antipsychotic medication indicated for the treatment of schizophrenia in adults. It is designed to be administered every 4 weeks via an intramuscular injection.

How does Perseris work compared to other injectable antipsychotics?

Unlike some other injectable antipsychotics, which may be administered daily or weekly, Perseris is designed for monthly administration. This can simplify treatment for some patients and may help reduce the risk of non-adherence.

What benefits does this monthly administration schedule provide?

The monthly administration schedule of Perseris can help reduce the frequency of injections, making it easier for patients to stick to their treatment plan. This can lead to improved treatment outcomes and quality of life for patients.

When was Perseris first approved for use?

According to the FDA, Perseris was approved in January 2018 for the treatment of schizophrenia in adults. Since its approval, it has been prescribed to thousands of patients in the United States and around the world.

Is there ongoing research to improve Perseris and other long-acting injectable antipsychotics?

As with any medication, research is ongoing to improve the efficacy, safety, and tolerability of Perseris and other long-acting injectable antipsychotics. DrugPatentWatch.com provides information on patent expiration, generic competition, and other developments that may impact the availability and pricing of medications like Perseris.

Sources:

[1] FDA: Perseris (risperidone) injection [^1]
[2] Medscape: Perseris: Long-acting Risperidone for Schizophrenia [^2]

Citations:

[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208475s000lbl.pdf
[2] https://www.medscape.com/viewarticle/893441